Docoh
Loading...

PNT POINT Biopharma Global

Filed: 18 Mar 21, 9:08am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 (Amendment No. 1)

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 16 , 2021 (March 15, 2021)

 

THERAPEUTICS ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware 001-39311 85-0800493
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I.R.S. Employer
Identification No.)

 

 200 Berkeley Street, 18th Floor

Boston, MA

 02116
(Address of principal executive offices) (Zip Code)

 

(617) 778.2540

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 ¨ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class Trading Symbols 

Name of each exchange on

 which registered

Class A common stock, par value $0.0001 per share RACA The Nasdaq Stock Market LLC

 

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Explanatory Note

 

This Amendment supplements Item 9.01 (solely to add additional exhibits) of the Current Report on Form 8-K of Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (the “Company”), filed with the Securities and Exchange Commission on March 15, 2021 (the “Original Current Report”), in which the Company reported, among other events, the execution of the Business Combination Agreement (as defined in the Original Current Report). Item 1.01, Item 3.02, and Item 7.01 of the Original Current Report remain unchanged. Interested parties should refer to the Original Current Report for Item 1.01, Item 3.02, and Item 7.01 and the prior exhibits filed pursuant to Item 9.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
2.1* Business Combination Agreement, dated as of March 15, 2021, by and between Therapeutics Acquisition Corp., Bodhi Merger Sub, Inc. and POINT BioPharma Inc.
10.1 Form of Sponsor Letter Agreement.

 

 *Certain exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Therapeutics Acquisition Corp.
   
 By:/s/ Matthew Hammond
  Name: Matthew Hammond
  Title:   Chief Financial Officer

 

Dated: March 16, 2021